Thank You, ISN Volunteers! Join the World's Largest International Kidney Care Organization - Renew Your ISN Membership Today
Among its thousands of dedicated members, the ISN is privileged to be guided by more than 1300 volunteers, ISN members who generously lend their expertise to ISN committees, granting programs, advocacy initiatives, special events and educational tools.
ISN CME Program Supports Two Speakers to Travel to India to Present on Pediatric Nephrology
In December 2022, the ISN supported members Valerie Luyckx (Switzerland) and Hui Kim Yap (Singapore) to present talks at the 34th National Conference of the Indian Society of Pediatric Nephrology in Mumbai, India.
Results From Part A of the Multi-center, Double-blind, Randomized, Placebo-controlled Nefigard Trial, Which Evaluated Targeted-release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy
To verify the findings of the 2b NEFIGAN trial, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon® versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure.
Nefecon® was well-tolerated and most adverse effects were mild to moderate in severity and reversible, confirming outcomes from the phase 2b NEFIGAN study.
A Pilot Randomized Trial of Intra-dialysis Yoga for Patients with End-stage Kidney Disease
This study evaluated the feasibility of conducting a randomized clinical pilot study to measure the effects of intradialytic yoga on quality of life, self-efficacy, and physical performance among maintenance hemodialysis patients. The feasibility and safety of such a trial were supported by the results.